Effectiveness of trivalent inactivated influenza vaccines in children during 2017-2018 season in Korea: Comparison of test-negative analysis by rapid and RT-PCR influenza tests.
Children
Inactivated influenza vaccine
Seasonal influenza
Vaccine effectiveness
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
23
05
2020
revised:
13
07
2020
accepted:
18
07
2020
pubmed:
28
7
2020
medline:
17
12
2020
entrez:
28
7
2020
Statut:
ppublish
Résumé
In Korea, the National Immunization Program provided trivalent inactivated influenza vaccines (IIV3) to all children aged 6-59 months during the 2017-2018 season. In this study, we aimed to evaluate the vaccine effectiveness (VE) of IIV3 in children during the 2017-2018 season. Children aged 6-59 months who were tested for influenza for their acute respiratory illness in four hospitals during the 2017-2018 influenza season were included. We estimated the VE of IIV3 by test-negative case-control design based on the rapid influenza diagnostic test (RIDT) or reverse transcription polymerase chain reaction (RT-PCR) test results. A total of 4738 children were included in this study. The number of laboratory-confirmed influenza cases was 845 (17.8%), and there were 478 cases of influenza A and 362 cases of influenza B. The adjusted VE based on RT-PCR was 53.4% (95% CI, 25.3-70.5) against any influenza, 68.8% (95% CI, 38.7-84.1) against influenza A, and 29.7% (95% CI, -35.1 to 61.8) for influenza B. The adjusted VE based on RIDT was 14.8% (95% CI, -4.4 to 30.0) against any influenza, 24.2% (95% CI, 3.1-40.2) against influenza A, and -5.1% (95% CI, -42.6 to 21.4) against influenza B. Age-specific VE based on RT-PCR against any influenza was 44.1% (95% CI, -0.2 to 67.8) in children aged 6 months to 2 years and 59.3% (95% CI, 8.8-81.9) in children aged 3-<5 years. Our results suggest moderate protection (53.4%) of IIV3 against RT-PCR laboratory-confirmed influenza in children in the 2017-2018 influenza season. However, the RIDT hampered the validity to assess VE during influenza season. Caution is needed when interpreting an RIDT-based test negative design influenza VE study.
Identifiants
pubmed: 32717398
pii: S1201-9712(20)30576-2
doi: 10.1016/j.ijid.2020.07.032
pmc: PMC7381399
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-203Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Hum Vaccin Immunother. 2019;15(1):97-101
pubmed: 30148689
Clin Infect Dis. 2012 Jan 1;54(1):25-32
pubmed: 22095567
Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Jun 6;53(6):576-580
pubmed: 31177753
Vaccine X. 2019 Jan 29;1:100011
pubmed: 31384733
Euro Surveill. 2016 Oct 20;21(42):
pubmed: 27784529
PLoS One. 2014 Feb 13;9(2):e88813
pubmed: 24551167
Pediatrics. 2014 May;133(5):e1218-25
pubmed: 24753525
Lancet. 2017 Aug 12;390(10095):697-708
pubmed: 28302313
Clin Infect Dis. 2019 Nov 13;69(11):1845-1853
pubmed: 30715278
Clin Infect Dis. 2019 May 2;68(10):1754-1757
pubmed: 30312364
Euro Surveill. 2017 Oct;22(43):
pubmed: 29090681
Front Pediatr. 2019 Jul 30;7:317
pubmed: 31417886
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):468-473
pubmed: 31774120
Euro Surveill. 2018 Feb;23(5):
pubmed: 29409570
Vaccine. 2018 Feb 14;36(8):1063-1071
pubmed: 29361343
Clin Infect Dis. 2019 Nov 27;69(12):2153-2161
pubmed: 30753347
Euro Surveill. 2018 Mar;23(13):
pubmed: 29616611
Vaccine. 2013 Jun 24;31(29):2974-8
pubmed: 23688524
Int J Infect Dis. 2015 Jan;30:115-21
pubmed: 25462180